A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin

Juhani U. Maenpaa, Gregory T. Wurz, W. Jeffrey Baker, Valerie J. Wiebe, Vernon D. Emshoff, Steven K. Koester, Robert C. Seymour, R. Ellen Koehler, Michael W. DeGregorio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The in vivo growth rate and the chemosensitivity patterns of a cell clone selected by tamoxifen from the estrogen receptor-negative human breast cancer cell line MDA-MB-231 was studied in the nude mouse model and with flow cytometry. To investigate the growth rate of the wild-type and clone cells in vivo, the cells were inoculated into the opposite flanks of 5 male nude mice. Drug sensitivity to doxorubicin (10 ng/mL), vinblastine (1 ng/mL), and paclitaxel (1 ng/mL) was examined in wild-type/clone cell mixture using flow cytometry. Northern blot technique was used to study the expression of mdr-1 messenger RNA in both the wild-type and the clone cells. The tumors derived from the clone and wild-type cells were, following a 3-week growth period, 260.2 ± 78.8 mm2 vs. 68.3 ± 50.8 mm2 in size, respectively (P < 0.001). Following a 28-day continuous exposure, doxorubicin was selectively toxic to the wild-type cells, while having no apparent effect on the clone population. However, paclitaxel- and vinblastine-treated wild-type/clone cell mixtures did not exhibit a differential cytotoxic effect on either cell population. It was concluded that the clone selected by tamoxifen shows an aggressive growth rate in vivo and an altered chemosensitivity pattern to doxorubicin in vitro.

Original languageEnglish (US)
Pages (from-to)461-466
Number of pages6
JournalOncology Research
Volume5
Issue number12
StatePublished - 1993
Externally publishedYes

Fingerprint

Tamoxifen
Doxorubicin
Clone Cells
Breast Neoplasms
Growth
Vinblastine
Paclitaxel
Nude Mice
Flow Cytometry
Poisons
Estrogen Receptors
Northern Blotting
Population
Cell Line
Messenger RNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

Maenpaa, J. U., Wurz, G. T., Baker, W. J., Wiebe, V. J., Emshoff, V. D., Koester, S. K., ... DeGregorio, M. W. (1993). A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin. Oncology Research, 5(12), 461-466.

A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin. / Maenpaa, Juhani U.; Wurz, Gregory T.; Baker, W. Jeffrey; Wiebe, Valerie J.; Emshoff, Vernon D.; Koester, Steven K.; Seymour, Robert C.; Koehler, R. Ellen; DeGregorio, Michael W.

In: Oncology Research, Vol. 5, No. 12, 1993, p. 461-466.

Research output: Contribution to journalArticle

Maenpaa, JU, Wurz, GT, Baker, WJ, Wiebe, VJ, Emshoff, VD, Koester, SK, Seymour, RC, Koehler, RE & DeGregorio, MW 1993, 'A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin', Oncology Research, vol. 5, no. 12, pp. 461-466.
Maenpaa JU, Wurz GT, Baker WJ, Wiebe VJ, Emshoff VD, Koester SK et al. A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin. Oncology Research. 1993;5(12):461-466.
Maenpaa, Juhani U. ; Wurz, Gregory T. ; Baker, W. Jeffrey ; Wiebe, Valerie J. ; Emshoff, Vernon D. ; Koester, Steven K. ; Seymour, Robert C. ; Koehler, R. Ellen ; DeGregorio, Michael W. / A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin. In: Oncology Research. 1993 ; Vol. 5, No. 12. pp. 461-466.
@article{88f3ebfed70f4605b912e181ad05f0d8,
title = "A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin",
abstract = "The in vivo growth rate and the chemosensitivity patterns of a cell clone selected by tamoxifen from the estrogen receptor-negative human breast cancer cell line MDA-MB-231 was studied in the nude mouse model and with flow cytometry. To investigate the growth rate of the wild-type and clone cells in vivo, the cells were inoculated into the opposite flanks of 5 male nude mice. Drug sensitivity to doxorubicin (10 ng/mL), vinblastine (1 ng/mL), and paclitaxel (1 ng/mL) was examined in wild-type/clone cell mixture using flow cytometry. Northern blot technique was used to study the expression of mdr-1 messenger RNA in both the wild-type and the clone cells. The tumors derived from the clone and wild-type cells were, following a 3-week growth period, 260.2 ± 78.8 mm2 vs. 68.3 ± 50.8 mm2 in size, respectively (P < 0.001). Following a 28-day continuous exposure, doxorubicin was selectively toxic to the wild-type cells, while having no apparent effect on the clone population. However, paclitaxel- and vinblastine-treated wild-type/clone cell mixtures did not exhibit a differential cytotoxic effect on either cell population. It was concluded that the clone selected by tamoxifen shows an aggressive growth rate in vivo and an altered chemosensitivity pattern to doxorubicin in vitro.",
author = "Maenpaa, {Juhani U.} and Wurz, {Gregory T.} and Baker, {W. Jeffrey} and Wiebe, {Valerie J.} and Emshoff, {Vernon D.} and Koester, {Steven K.} and Seymour, {Robert C.} and Koehler, {R. Ellen} and DeGregorio, {Michael W.}",
year = "1993",
language = "English (US)",
volume = "5",
pages = "461--466",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "12",

}

TY - JOUR

T1 - A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin

AU - Maenpaa, Juhani U.

AU - Wurz, Gregory T.

AU - Baker, W. Jeffrey

AU - Wiebe, Valerie J.

AU - Emshoff, Vernon D.

AU - Koester, Steven K.

AU - Seymour, Robert C.

AU - Koehler, R. Ellen

AU - DeGregorio, Michael W.

PY - 1993

Y1 - 1993

N2 - The in vivo growth rate and the chemosensitivity patterns of a cell clone selected by tamoxifen from the estrogen receptor-negative human breast cancer cell line MDA-MB-231 was studied in the nude mouse model and with flow cytometry. To investigate the growth rate of the wild-type and clone cells in vivo, the cells were inoculated into the opposite flanks of 5 male nude mice. Drug sensitivity to doxorubicin (10 ng/mL), vinblastine (1 ng/mL), and paclitaxel (1 ng/mL) was examined in wild-type/clone cell mixture using flow cytometry. Northern blot technique was used to study the expression of mdr-1 messenger RNA in both the wild-type and the clone cells. The tumors derived from the clone and wild-type cells were, following a 3-week growth period, 260.2 ± 78.8 mm2 vs. 68.3 ± 50.8 mm2 in size, respectively (P < 0.001). Following a 28-day continuous exposure, doxorubicin was selectively toxic to the wild-type cells, while having no apparent effect on the clone population. However, paclitaxel- and vinblastine-treated wild-type/clone cell mixtures did not exhibit a differential cytotoxic effect on either cell population. It was concluded that the clone selected by tamoxifen shows an aggressive growth rate in vivo and an altered chemosensitivity pattern to doxorubicin in vitro.

AB - The in vivo growth rate and the chemosensitivity patterns of a cell clone selected by tamoxifen from the estrogen receptor-negative human breast cancer cell line MDA-MB-231 was studied in the nude mouse model and with flow cytometry. To investigate the growth rate of the wild-type and clone cells in vivo, the cells were inoculated into the opposite flanks of 5 male nude mice. Drug sensitivity to doxorubicin (10 ng/mL), vinblastine (1 ng/mL), and paclitaxel (1 ng/mL) was examined in wild-type/clone cell mixture using flow cytometry. Northern blot technique was used to study the expression of mdr-1 messenger RNA in both the wild-type and the clone cells. The tumors derived from the clone and wild-type cells were, following a 3-week growth period, 260.2 ± 78.8 mm2 vs. 68.3 ± 50.8 mm2 in size, respectively (P < 0.001). Following a 28-day continuous exposure, doxorubicin was selectively toxic to the wild-type cells, while having no apparent effect on the clone population. However, paclitaxel- and vinblastine-treated wild-type/clone cell mixtures did not exhibit a differential cytotoxic effect on either cell population. It was concluded that the clone selected by tamoxifen shows an aggressive growth rate in vivo and an altered chemosensitivity pattern to doxorubicin in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0027893155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027893155&partnerID=8YFLogxK

M3 - Article

C2 - 8086667

AN - SCOPUS:0027893155

VL - 5

SP - 461

EP - 466

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 12

ER -